SERD zeigt anti-proliferative Aktivität bei frühem ER+/HER2-Brustkrebs, berichtet ESMO Daily Reporter.

Quelle: ESMO Daily Reporter
Link: https://dailyreporter.esmo.org/esmo-breast-cancer-2026/latest-news/serd-therapy-demonstrates-robust-anti-proliferative-activity-in-young-patients-with-er-positive-her2-negative-early-breast-cancer